Tag Archives: Walgreens

CLDF to Support Free HCV Testing at 60 Walgreens Stores across the U.S.

CLARK, N.J., May 19, 2015 /PRNewswire/ — The Chronic Liver Disease Foundation (CLDF) announced today that it’s collaborating with Walgreens
to offer free hepatitis C (HCV) testing with the OraQuick® HCV Rapid
Test at more than 60 Walgreens retail pharmacies in 12 major cities
throughout the country.

The program, which is slated to launch this August
and run through January 2016, will offer free rapid HCV testing on
specific days and times each week to patients at risk for HCV. Rapid
testing and patient education will be conducted by trained healthcare
professionals on site at each retail location and individuals who test
positive will be linked directly to one of CLDF’s 75 Hepatology Centers
of Expertise throughout the U.S.

“The rapid hepatitis testing program demonstrates
our commitment to helping patients access important information that can
help to improve their health,” said Glen Pietrandoni, RPh, AAHIVP,
senior director, virology, Walgreens. “We are proud to collaborate with
the Chronic Liver Disease Foundation on this initiative. Through this
testing program we can help people become educated on the risk factors,
identify people infected with HCV and help them get linked to
appropriate care.”

“Today, approximately 5.2 million Americans have
hepatitis C and the vast majority does not know it,” said Dr. Willis C.
Maddrey, President of the Chronic Liver Disease Foundation. “However,
new therapies are now available that can effectively treat and cure
hepatitis C.

Each year, about 17,000 Americans become infected
with hepatitis C. Up to 75 percent of people with chronic hepatitis C
infection were born during 1945-1965, and up to three out of four people
infected with hepatitis C are unaware of their infection.

OraQuick® HCV is the first and only FDA-approved
and CLIA-waived point of care test for detection of HCV infection in
at-risk individuals. The simple, accurate platform enables healthcare
providers to deliver an accurate diagnosis in 20 minutes, using
venipuncture or fingerstick blood. The test is manufactured by OraSure
Technologies

Established in 2001, the Chronic Liver Disease Foundation is a nonprofit
501(c)(3) educational organization dedicated to providing hepatology
related continuing medical education, news and information to healthcare
professionals across the US. The CLDF is led by a Board of Trustees
comprised of nationally renowned liver disease specialists. Furthermore,
the CLDF believes that educational programs should be developed by the
specialists who are actively involved in the research, treatment and
management of a disease. As such the CLDF has developed a network of 75
Centers of Educational Expertise and multiple Advisory Boards who are
actively involved in program creation related to specific disease topics
which include; hemochromatosis, hepatic encephalopathy, hepatitis B,
hepatitis C, hepatocellular carcinoma, HIV co-infection, liver
transplantation and NASH/NAFLD. The CLDF’s educational opportunities are
offered in a variety of formats including an interactive web site, live
meetings, teleconferences, print pieces, webcasts and other electronic
mediums. For more information, please visit www.chronicliverdisease.org.

CLDF to Support Free HCV Testing at 60 Walgreens Stores across the U.S.

CLARK, N.J., May 19, 2015 /PRNewswire/ — The Chronic Liver Disease Foundation (CLDF) announced today that it’s collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick® HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country.

The program, which is slated to launch this August and run through January 2016, will offer free rapid HCV testing on specific days and times each week to patients at risk for HCV. Rapid testing and patient education will be conducted by trained healthcare professionals on site at each retail location and individuals who test positive will be linked directly to one of CLDF’s 75 Hepatology Centers of Expertise throughout the U.S.

“The rapid hepatitis testing program demonstrates our commitment to helping patients access important information that can help to improve their health,” said Glen Pietrandoni, RPh, AAHIVP, senior director, virology, Walgreens. “We are proud to collaborate with the Chronic Liver Disease Foundation on this initiative. Through this testing program we can help people become educated on the risk factors, identify people infected with HCV and help them get linked to appropriate care.”

“Today, approximately 5.2 million Americans have hepatitis C and the vast majority does not know it,” said Dr. Willis C. Maddrey, President of the Chronic Liver Disease Foundation. “However, new therapies are now available that can effectively treat and cure hepatitis C.

Each year, about 17,000 Americans become infected with hepatitis C. Up to 75 percent of people with chronic hepatitis C infection were born during 1945-1965, and up to three out of four people infected with hepatitis C are unaware of their infection.

OraQuick® HCV is the first and only FDA-approved and CLIA-waived point of care test for detection of HCV infection in at-risk individuals. The simple, accurate platform enables healthcare providers to deliver an accurate diagnosis in 20 minutes, using venipuncture or fingerstick blood. The test is manufactured by OraSure Technologies OSUR, -0.16% in Bethlehem, Pa.About the Chronic Liver Disease FoundationEstablished in 2001, the Chronic Liver Disease Foundation is a nonprofit 501(c)(3) educational organization dedicated to providing hepatology related continuing medical education, news and information to healthcare professionals across the US. The CLDF is led by a Board of Trustees comprised of nationally renowned liver disease specialists. Furthermore, the CLDF believes that educational programs should be developed by the specialists who are actively involved in the research, treatment and management of a disease. As such the CLDF has developed a network of 75 Centers of Educational Expertise and multiple Advisory Boards who are actively involved in program creation related to specific disease topics which include; hemochromatosis, hepatic encephalopathy, hepatitis B, hepatitis C, hepatocellular carcinoma, HIV co-infection, liver transplantation and NASH/NAFLD. The CLDF’s educational opportunities are offered in a variety of formats including an interactive web site, live meetings, teleconferences, print pieces, webcasts and other electronic mediums. For more information, please visit www.chronicliverdisease.org.

Walgreens now offers more than 100 hepatitis C-specialized pharmacies
with new hepatitis C virus (HCV) medications available and pharmacists
specially trained on next generation oral therapies. Walgreens hepatitis
C specially-trained pharmacists are also qualified to identify
HCV-associated health concerns and can provide hepatitis C patient care
for those with a HIV co-infection or other comorbid conditions, such as
diabetes or high blood pressure. The specialized support has been proven
to benefit patients, contributing to 90 percent adherence for patients
who completed past treatments .

The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients. To read the entire study, click here Share This PageFollow Us … Continue reading → The post The study is aimed at assessing the safety and immunogenicity of HCV […]

The purpose of this study is to evaluate the efficacy and tolerability of DAA-based regimens in the clinical practice in HIV/HCV-coinfected patients. Hypothesis: The efficacy and tolerability of all DAA-based regimens in the clinical practice is different to what is … Continue reading → The post Real-life Security and Efficacy of DAA-based Therapy in 1,000 […]